Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 3,172 Shares of Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Todd Watanabe sold 3,172 shares of Arcutis Biotherapeutics stock in a transaction on Monday, May 4th. The stock was sold at an average price of $23.61, for a total transaction of $74,890.92. Following the transaction, the insider directly owned 720,755 shares in the company, valued at $17,017,025.55. This represents a 0.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Todd Watanabe also recently made the following trade(s):

• On Monday, March 2nd, Todd Watanabe sold 37,349 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.18, for a total transaction of $940,447.82.

Arcutis Biotherapeutics Stock Up 3.2%

ARQT traded up $0.75 during mid-day trading on Wednesday, reaching $24.17. 1,381,968 shares of the stock were exchanged, compared to its average volume of 1,329,167. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.99 and a current ratio of 3.17. The stock has a market capitalization of $3.02 billion, a PE ratio of -172.63 and a beta of 1.58. The company has a 50 day moving average price of $23.82 and a two-hundred day moving average price of $25.75. Arcutis Biotherapeutics, Inc. has a 1 year low of $12.42 and a 1 year high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07). The firm had revenue of $105.40 million for the quarter, compared to analysts’ expectations of $103.68 million. Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of 4.29%. As a group, research analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.18 EPS for the current year.

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Independent Financial Group LLC bought a new stake in Arcutis Biotherapeutics in the 1st quarter valued at about $210,000. Bank of New York Mellon Corp raised its stake in Arcutis Biotherapeutics by 0.4% in the 1st quarter. Bank of New York Mellon Corp now owns 305,532 shares of the company’s stock valued at $7,198,000 after acquiring an additional 1,104 shares during the period. Hillsdale Investment Management Inc. raised its stake in Arcutis Biotherapeutics by 4.9% in the 1st quarter. Hillsdale Investment Management Inc. now owns 188,220 shares of the company’s stock valued at $4,434,000 after acquiring an additional 8,800 shares during the period. Principal Financial Group Inc. bought a new stake in Arcutis Biotherapeutics in the 1st quarter valued at about $3,978,000. Finally, Candriam S.C.A. raised its stake in Arcutis Biotherapeutics by 35.3% in the 1st quarter. Candriam S.C.A. now owns 1,086,651 shares of the company’s stock valued at $25,601,000 after acquiring an additional 283,513 shares during the period.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ARQT shares. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. HC Wainwright boosted their price target on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Mizuho cut their price target on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Guggenheim boosted their price target on shares of Arcutis Biotherapeutics from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, TD Cowen boosted their price target on shares of Arcutis Biotherapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Arcutis Biotherapeutics News Summary

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Q1 product momentum — ZORYVE net product revenue was $105.4M, up ~65% year‑over‑year and above consensus revenue; company said it maintained positive operating cash flow and highlighted continued branded non‑steroidal share gains. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Regulatory and pipeline progress — submitted an sNDA to expand ZORYVE for infants (3–24 months), completed enrollment in the ZORYVE foam pediatric MUSE trial, and started first‑in‑human studies of ARQ‑234. These catalysts support longer‑term growth expectations. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Commercial build — expanded the dermatology sales force and is building a primary care/pediatrics organization, which could broaden ZORYVE adoption. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analyst stance — broker consensus remains a “Moderate Buy,” supporting investor sentiment around upside to the current share price. Arcutis Receives Consensus Recommendation of “Moderate Buy”
• Neutral Sentiment: Insider sales disclosed — several executives and a director sold shares recently (executed under pre‑arranged Rule 10b5‑1 plans and largely to cover taxes on vested awards), which is typical after vesting and less likely to signal negative insider sentiment. Representative SEC filing: Todd Watanabe Form 4

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.